In a ROC analysis, IL-8 concentration at baseline was the best discriminator in both AHSCT-treated patients with EDA [AUC = 0.84 (95% confidence interval (CI): 0.69–0.95)] and PMS patients treated with ITRTX and CDW [AUC = 0.92 (95% CI: 0.80–1.0)]. This evidence concerns the gene CXCL8 and hypohidrotic ectodermal dysplasia.